Peroxiredoxin proteins protect MCF-7 breast cancer cells from doxorubicin-induced toxicity

International Journal of Oncology

Volumn 45, Issue 1, 2014, Pages 219-226

  McDonald, C ^a   Muhlbauer, J ^a   Perlmutter, G ^a   Taparra, K ^a,b   Phelan, Shelley A ^a  

^a FAIRFIELD UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidants; Breast cancer; Cell death; Doxorubicin; MCF 7; Peroxiredoxins

Indexed keywords

DOXORUBICIN; PEROXIREDOXIN; PEROXIREDOXIN 1; PEROXIREDOXIN 2; PEROXIREDOXIN 3; PEROXIREDOXIN 4; PEROXIREDOXIN 5; PEROXIREDOXIN 6; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER SURVIVAL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME INDUCTION; ENZYME REPRESSION; GENE OVEREXPRESSION; LONG TERM EXPOSURE; MCF 7 CELL LINE; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSIENT TRANSFECTION; WESTERN BLOTTING; BREAST TUMOR; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; PEROXIREDOXINS;

EID: 84902587407     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2398     Document Type: Article

References (33)

1. Fujii J and Ikeda Y: Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep 7: 123-130, 2002.
2. Hofmann B, Hecht HJ and Flohe L: Peroxiredoxins. Biol Chem 383: 347-364, 2002.
3. Wood ZA, Schröder E, Harris JR and Poole LB: Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28: 32-40, 2003.
4. Immenschuh S and Baumgart-Vogt E: Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal 7: 768-777, 2005.
5. Rhee SG, Chae HZ and Kim K: Peroxiredoxins: A historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Rad Biol Med 38: 1543-1552, 2005.
6. Halliwell B and Gutteridge J: Free Radicals in Biology and Medicine. 3rd edition. Oxford University Press, New York, NY, 1999.
7. Halliwell B: Oxidative stress and cancer: have we moved forward? Biochem J 401: 1-11, 2007.
8. Valko M, Rhodes CJ, Moncol J, Izakovic M and Mazur M: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160: 1-40, 2006.
9. Butterfield LH, Merino A, Golub SH and Shau H: From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins. Antioxid Redox Signal 1: 385-402, 1999.
10. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA and Chae HZ: Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 21: 2085-2090, 2001.
11. Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG and Soini Y: Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 196: 316-323, 2002.
12. Karihtala, P, Mantyniemi A, Kang SW, Kinnula VL and Soini Y: Peroxiredoxins in breast carcinoma. Clin Cancer Res 15: 3418-3424, 2003.
13. Lehtonen ST, Svensk AM, Soini Y, Paakko P, Hirvikoski P, Kang SW and Saily M: Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 111: 514-521, 2004.
14. Quan C, Cha EJ, Lee HL, Han KH, Lee KM and Kim WJ: Enhanced expression of peroxiredoxin I and VI correlates with development recurrence and progression of human bladder cancer. J Urolol 175: 1512-1516, 2006.
15. Kinnula VL, Paakko P and Soini Y: Antioxidant enzymes and redox regulating thiol proteins in malignancies of human lung. FEBS Lett 569: 1-6, 2004.
16. Li DQ, Wang L, Fei F, Hou YF, Luo JM, Wei-Chen, Zeng R, Wu J, Lu JS, Di GH, Ou ZL and Xia QC: Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 6: 3352-3368, 2006.
17. Neumann CA and Fang Q: Are peroxiredoxins tumor suppressors? Curr Opin Pharm 7: 375-380, 2007.
18. Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL and Shen ZZ: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 9: R76, 2007.
19. Ishii T, Warabi E and Yanagawa T: Novel roles of peroxiredoxins in inflammation, cancer and innate immunity. J Clin Biochem Nutr 50: 91-105, 2012.
20. Chahed K, Kabbage M, Hamrita B, Guillier CL, Trimeche M, Remadi S, Ehret-Sabatier L and Chouchane L: Detection of protein alterations in male breast cancer using two dimensional gel electrophoresis and mass spectrometry: The involvement of several pathways in tumorigenesis. Clin Chim Acta 388: 106-114, 2008.
21. Coley HM: Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 34: 378-390, 2008.
22. 2-induced cell death in MCF-7 Cell Lines. J Cell Biochem 101: 1038-1045, 2007.
23. Goncalves K, Sullivan K and Phelan SA: Differential expression and function of peroxiredoxin 1 and peroxiredoxin 6 in cancerous MCF-7 and noncancerous MCF-10A breast epithelial cells. Cancer Invest 30: 38-47, 2012.
24. Tehan L, Taparra K and Phelan SA: Peroxiredoxin overexpression in MCF-7 breast cancer cells and regulation by cell proliferation and oxidative stress. Cancer Invest 31: 374-384, 2013.
25. Wang T, Tamae D, LeBon T, Shively JE, Yen Y and Li JJ: The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res 65: 10338-10346, 2005.
26. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11: 121-139, 1992.
27. Osbild S, Brault L, Battaglia E and Bagrel D: Resistance to cisplatin and adriamycin is associated with the inhibition of glutathione efflux in MCF-7-derived cells. Anticancer Res 26: 3595-3600, 2006.
28. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S and Yamamoto M: Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 275: 16023-16029, 2000.
29. Wonsey DR, Zeller KI and Dang CV: The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA 99: 6649-6654, 2002.
30. Li L, Zhang YG and Chen CL: Anti-apoptotic role of peroxiredoxin III in cervical cancer cells. FEBS Open Bio 3: 51-54, 2012.
31. Gajewski E, Gaur S, Akman SA, Matsumoto L, van Balgooy JNA and Doroshowa JH: Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin. Biochem Pharmacol 73: 1947-1956, 2007.
32. Diaz AJG, Tamae D, Yen Y, Li JJ and Wang T: Enhanced radiation response in radioresistant MCF-7 cells by targeting peroxiredoxin II. Breast Cancer (Dove Med Press) 5: 87-101, 2013.
33. He T, Banach-Latapy A, Vernis L, Dardalhon M, Chanet R and Huang ME: Peroxiredoxin 1 knockdown potentiates β-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals. Carcinogenesis 34: 760-769, 2013.